Physician profile
Lee Barnwell
NPI 1720600950
$1,189.97
in general payments reported to CMS, 2019-2025
23 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $120 · 2024: $601 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $232.12 | 2023-2025 | Vraylar |
| Axsome Therapeutics, INC. | $189.08 | 2024-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $135.20 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $122.67 | 2023-2024 | Austedo Xr, Uzedy |
| Dexcom, INC. | $65.18 | 2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $50.34 | 2024-2025 | Ingrezza |
| Lilly USA, LLC | $43.61 | 2024-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $41.53 | 2024-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $37.64 | 2024-2025 | Trelegy Ellipta |
| Sage Therapeutics, LLC | $35.73 | 2024-2025 | Zurzuvae |
| Tris Pharma INC | $23.92 | 2025 | Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $22.00 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $20.21 | 2023 | Rexulti |
| Phathom Pharmaceuticals, INC. | $19.88 | 2024 | Voquezna |
| Pfizer INC. | $18.77 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.16 | 2025 | Caplyta |
| Alkermes, INC. | $17.95 | 2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $17.69 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $17.16 | 2023 | Spravato |
| Astellas Pharma US INC | $16.94 | 2025 | Veozah |
| Tonix Medicines, INC. | $15.92 | 2025 | Tonmya |
| Exact Sciences Corporation | $14.78 | 2024 | Cologuard Collection Kit |
| Corium, LLC | $13.49 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Barnwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.